ClinicalTrials.gg
Active, not recruitingNCT05817110CREATEUpdated Aug 20, 2026

Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.

An observational study in Lung Malignancy, sponsored by AstraZeneca. Active, not recruiting at 22 sites in 5 countries. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by AstraZeneca · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
712
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 63 studies in Lung Neoplasms by AstraZeneca — 12 open to participants now, 22 under way, 3 of them phase 3. Lung Neoplasms · AstraZeneca.

Enrollment
13th of 30
712 · median 568
Started
2023
with 2 others
Observational
30 of 63
9 open now
Primary completion
2026-12
later than 6 of 21 live
Registered
45th of 63
by date

Among the 63 studies in Lung Neoplasms by AstraZeneca, this one is the 13th largest by enrollment of the 30 observational ones that give a count, is one of 3 that started in 2023, is one of 30 observational ones, reaches primary completion later than 6 of the 21 other live ones, and was the 45th registered.

Lung Neoplasms

5,432 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

12 of the 63 studies in Lung Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Lung Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

Artificial intelligence (AI) based algorithms have demonstrated increased accuracy in predicting the risk of Lung Cancer among patients with an incidental pulmonary nodule (IPN) on chest radiographs. Qure.ai, an AI company specializing in the reading of chest X- Rays (CXRs) by a proprietary algorithm and has developed a new model, qXR, that can report the lung nodule malignancy score (LNMS) based on lung nodule features.

Our study aims to prospectively validate the lung nodule malignancy score against radiologist assessment of CT scans and Lung CT Screening Reporting and Data System score (Lung-RADS).(lung RADS score explained below) Thus, lung nodule malignancy score (interpreted by qXR as a high or low category) will be compared with radiologist-based assessment probability of CT scan and Lung-RADS assessment. The results of this prospective observational study will pave the way for improved nodule management, leading to better clinical outcomes in patients with incidental pulmonary nodule (IPNs), especially concerning malignancy assessment.

Read the detailed description

A multicentric, multinational, prospective, observational study to validate qXR-Lung nodule malignancy score as a binary categorization of the risk of Lung cancer as high or low among patients with an incidental pulmonary nodule (IPN) on chest radiographs. The study will be implemented across selected countries in the AstraZeneca International Region (e.g., Philippines, Malaysia, Saudi Arabia, United Arab Emirates, Kuwait, Thailand, Taiwan, Hong Kong, India, Brazil, Argentina, Colombia).

Patients coming to the facility for x-rays for any reason will undergo x-rays as ordered by their treating clinician. Adult patients diagnosed with incidental pulmonary nodule( IPN) on Chest X-ray (CXR) with nodule size ≥8 and ≤30 mm, will be invited to participate in the study and enrolled after obtaining their written informed consent. In case of any nodule detection by qXR, it will be classified either as low-risk Lung nodule malignancy score (LNMS) or high-risk LNMS. The X-ray reporting physician will decide the qXR report for the presence of a nodule.

CT scan will be performed after obtaining consent for the low-dose CT scan from patients.The clinical site's radiologist and an independent radiologist not associated with the clinical site will report the CT scan and the qXR-LNMS category. Radiologists' interpretation will be based on examining a nodule on a CT scan film (naked eye examination). Radiologists will first rate their CT scan interpretation of the nodule on the Likert scale as: non-malignant: 1; probable non-malignant: 2; uncertain: 3; probable malignant: 4; malignant: 5. In addition, the radiologists will assign a Lung-RADS and then give an overall assessment of the risk of malignancy as high or low.

. This study is minimal to no risk to the patient. The study duration for a participant will be approximately 30 months from the enrolment. The study will have 2 phases. Phase 1 will be from enrolment until CT data collection. The CT data collection day will end Phase 1 (End of Phase-1). Phase 2 will be from CT data collection until 24 months from CT which is the end of Phase 2. The study visits in this period will be per clinical follow-up and will not be mandatory.

03

Conditions studied

  • Lung Malignancy

Browse trials for

Keywords

  • Artificial Intelligence
  • Lung malignancy nodule score
  • Pulmonary Nodule
  • qXR-LNMS
  • Lung Cancer
  • Lung RADS
  • CT scan
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults patient (35years or more) coming for chest X-ray at the institution.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged >35 years
  • Patients diagnosed with incidental pulmonary nodule (IPN) on CXR (chest x-ray) by qXR and confirmed by the radiologist at the site with nodule size ≥8 and ≤30 mm.

Exclusion criteria

Exclusion Criteria:

  • Any medical or other for a CT scan
  • Nondigital (chest x-ray)CXR
  • CT scan is done more than 6 months after (chest x-ray) CXR
  • Patients with already diagnosed lung cancer
  • The patients referred for an X-Ray for a suspicious Lung cancer
  • A patient who already participated in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
712 participants (actual)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • Computed tomography Cohort

    In case of any nodule detection by qXR, it will be classified either as low-risk LNMS(lung nodule malignancy score ) or high-risk LNMS confirmed by radiologist. The patient will be requested to get a CT scan after enrolment in the study.

    Other: Participant Cohort

Interventions

  • OtherParticipant Cohort

    Patients coming to the facility for chest x-rays for any reason, will undergo x-rays as ordered by their treating clinician. In case of any nodule detection by qXR, it will be classified either as low-risk (Lung nodule malignancy score ) LNMS or high-risk LNMS confirmed by radiologist. Then if patient is eligible will be included in the study and a CT Scan will be requested upon enrolment of the patient.

06

What researchers measure

Primary outcomes

  1. To estimate the positive and negative predictive values of qXR LNMS (lung nodule malignancy score ) in a multi-centre real-world setting.

    PPV( positive predictive value) of qXR-LNMS using a panel of radiologists assigning high-risk based on CT (done within 180 days from Xray) as the reference standard The PPV here is the number of nodules rated as high risk as assessed by a reference standard (a panel of radiologists) on CT divided by the total number of high-risk nodules as reported by qXR-LNMS (lung nodule malignancy score ) (n = 500) NPV( negative predictive value) of qXR-LNMS using panel of radiologists assigning low-risk based on CT (done within 180days from X-ray) as reference standard. The NPV here is number of nodules rated as low risk as assessed by a reference standard (a panel of radiologists) on CT divided by total number of low-risk nodules as reported by qXR-LNMS (lung nodule malignancy score ) (n = 200)

    Time frame: 6 months from the Last subject In.

Secondary outcomes

  1. Demographic and clinical factors associated with high or low predictive values association of qXR LNMS with the Mayo score model.

    PPV (positive predictive value) of qXR-LNMS (lung nodule malignancy score) using panel of radiologists assigning Lung-RADS (lung RADS score explained in description )\>4A based on CT as reference standard. The PPV here is number of nodules rated as Lung-RADS\>4A as assessed by a reference standard (a panel of radiologists) on CT divided by total number of high-risk nodules as reported by qXR-LNMS (n = 500) NPV ( negative predictive value) of qXR-LNMS using a panel of radiologists assigning Lung-RADS\<4A based on CT as the reference standard The NPV here is the number of nodules rated as Lung-RADS\<4A as assessed by a reference standard (a panel of radiologists) on CT divided by the total number of low-risk nodules as reported by qXR-LNMS (n = 200)

    Time frame: 2 and half years from Last subject In.

07

Study locations

22 sites
  • Research Site
    Alexandria, Egypt
  • Research Site
    Cairo, Egypt
  • Research Site
    Gurugram, Haryana 122001, India
  • Research Site
    New Delhi, National Capital Territory of Delhi 110005, India
  • Research Site
    New Delhi, National Capital Territory of Delhi 110017, India
  • Research Site
    New Delhi, National Capital Territory of Delhi 201012, India
  • Research Site
    Hyderabad, Telangana 500003, India
  • Research Site
    Bangalore, 560011, India
  • Research Site
    Bangalore, 560038, India
  • Research Site
    Chennai, 600026, India
  • Research Site
    Chennai, 600040, India
  • Research Site
    Chennai, 600045, India
  • Research Site
    Chennai, 600053, India
  • Research Site
    Chennai, 600116, India
  • Research Site
    Kolkata, 700025, India
  • Research Site
    Mumbai, 400069, India
  • Research Site
    Pune, 411011, India
  • Research Site
    Surabaya, 60286, Indonesia
  • Research Site
    Monterrey, Nuevo León 64460, Mexico
  • Research Site
    Mexico City, 6720, Mexico
  • Research Site
    Ankara, Turkey 06100, Turkey (Türkiye)
  • Research Site
    Mersin, Turkey 33010, Turkey (Türkiye)
08

References and documents

Publications

  • Koksal D, Govindarajan A, Gonuguntla HK, Nayci S, Cordova R, Zidan MH, McCutcheon S, Saha A, Kantharaju P, Sen S, Agrawal R, Wulandari L. Evaluation of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Incidental Pulmonary Nodules: The CREATE Study. Mayo Clin Proc Digit Health. 2026 Jan 19;4(1):100335. doi: 10.1016/j.mcpdig.2026.100335. eCollection 2026 Mar. PubMed 41716936 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Of 90 industry-sponsored observational studies under Lung Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 43 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Apr 18, 2023
StartActual
Apr 20, 2023
Primary completionEst.
Dec 6, 2026
CompletionEst.
Dec 6, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05817110
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Apr 20, 2023
Primary completion
Dec 6, 2026 (estimated)
Completion
Dec 6, 2026 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion